Mariner
SGMT icon

Mariner’s Sagimet Biosciences SGMT Stock Holding History

Mariner’s Portfolio SGMT Stock Details SGMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$203K Buy
38,800
+6,700
+21% +$37.3K ﹤0.01% 3156
2025
Q4 		$190K Buy
32,100
+7,000
+28% +$50.3K ﹤0.01% 3187
2025
Q3 		$172K Buy
25,100
+10,200
+68% +$82.7K ﹤0.01% 3226
2025
Q2 		$114K Hold
14,900
– – ﹤0.01% 3218
2025
Q1 		$48.6K Buy
+14,900
New +$62.5K ﹤0.01% 3314

Other funds holding SGMT

VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Mariner's SGMT Position: Q1 2026 in Review

Mariner increased its Sagimet Biosciences (SGMT) stake by 21% in Q1 2026, buying an estimated $37.3K and bringing the position to 38,800 shares worth $203K. The position accounts for ﹤0.01% of the portfolio, ranked #3156.

Mariner first reported a position in SGMT in Q1 2025 and has held it in 5 quarters since. 88 funds tracked by Wall St. Rank hold SGMT as of Q1 2026.

  • Mariner held 38,800 shares of Sagimet Biosciences worth $203K as of Q1 2026.
  • Mariner bought 6,700 Sagimet Biosciences shares in Q1 2026, an estimated $37.3K.
  • Sagimet Biosciences made up ﹤0.01% of Mariner's portfolio in Q1 2026, its #3156 holding.
  • Mariner first reported a position in Sagimet Biosciences in Q1 2025 and has held it in 5 quarters since.
  • 88 funds tracked by Wall St. Rank held Sagimet Biosciences as of Q1 2026.

Based on Mariner's 13F filing for Q1 2026, filed 13 May 2026.